SCHEMBL7467378

SCHEMBL7467378

FC1CCN(C2CN(C(c3ccccc3)c3ccccc3)C2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
OPRM1 P35372 4/20 0.43
HTR2B P41595 2/20 0.43
CHRM2 P08172 1/20 0.43
CHRM4 P08173 1/20 0.43
CHRM5 P08912 1/20 0.43
ADRA2A P08913 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
CYP2D6 P10635 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
DRD1 P21728 1/20 0.43
ADRA1D P25100 1/20 0.43
HTR2A P28223 1/20 0.43
HTR2C P28335 1/20 0.43
HRH1 P35367 1/20 0.43
DRD3 P35462 1/20 0.43
SLC6A3 Q01959 1/20 0.43
KCNH2 Q12809 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4261834 0.85 L3MBTL3 (0.55) L3MBTL3L3MBTL1OPRM1HTR2BCHRM2
SCHEMBL4957515 0.84 L3MBTL3 (0.51) L3MBTL3L3MBTL1OPRM1HTR2BCHRM2
SCHEMBL3263017 0.84 L3MBTL3 (0.72) L3MBTL3L3MBTL1OPRM1HTR2BCHRM2
SCHEMBL3069120 0.84 L3MBTL3 (0.67) L3MBTL3L3MBTL1OPRM1HTR2BCHRM2
SCHEMBL17460137 0.84 SLC18A3 (0.57) L3MBTL3L3MBTL1CYP2D6KMT2AALDH1A1
SCHEMBL6948721 0.83 L3MBTL3 (0.53) L3MBTL3L3MBTL1OPRM1HTR2BCHRM2
SCHEMBL3311978 0.83 L3MBTL3 (0.70) L3MBTL3L3MBTL1OPRM1HTR2BCHRM2
SCHEMBL6840171 0.83 L3MBTL3 (0.70) L3MBTL3L3MBTL1OPRM1HTR2BCHRM2
SCHEMBL7468276 0.83 CYP2D6 (0.44) L3MBTL3L3MBTL1OPRM1CHRM2CYP2D6
SCHEMBL493687 0.81 L3MBTL1 (0.51) L3MBTL3L3MBTL1OPRM1HTR2BHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140335050-A1 METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER THE GENERAL HOSPITAL CORPORATION (US) 2014-11-13 US disclosed
EP-0888337-B1 PIPERIDONE TACHYKININ ANTAGONISTS PFIZER RES & DEV (IE) 2002-06-05 EP disclosed
US-6262075-B1 Piperidone tachykinin antagonists PFIZER INC 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140335050-A1 METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER IL2RA, CD74, IL2 L3MBTL3 3924/4885L3MBTL1 4111/4885OPRM1 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.